Abstract:The myeloid-derived suppressor cell (MDSC)-mediated immunosuppressive tumor microenvironment (TME), where tumor hypoxia counts for much, has greatly compromised the outcome of cancer immunotherapy. Here, we demonstrated a strategy for selectively clearing intratumoral MDSCs. Specifically, 2-[2-[2-chloro-3-[(1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-propylindolium iodide (IR-780) and metformin (Met) were coloaded into mesoporous silica nanoparticles (MSNs) with CeO2 as the gatekeepers. Controlled release of cargos was achieved upon etching CeO2 with endogenous H2O2. Apart from the drug release, oxygen (O2) was also generated in this process. Importantly, the engagement of Met significantly inhibited mitochondrial respiration, thus working like an O2 economizer. Consequently, the populations and functions of tumor-infiltrated MDSCs were both dramatically reduced through selective alleviation of hypoxia at tumor sites, thus contributing to boosted immune responses. Additionally, the accumulated O2 enhanced IR780-mediated photodynamic therapy, which synergistically strengthened the antitumor efficacy of the platform. To the best of our knowledge, this is the first time to employ an O2-generated and -economized nanoplatform for selectively anergizing MDSC-mediated immunosuppression. We expect that this strategy will shed new light on the clinical cancer immunotherapy treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c18180?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c18180</a>.In vitro release profile of IR780 and Met from CeO2@/Met nanoparticles in plasma. Degradation of H2O2 by CeO2 NPs and the release of O2. Positive area of Ki-67 in tumor tissues after indicated treatments. Positive area of TUNEL in tumor tissues after indicated treatments. Survival curves of B16F10 tumor-bearing mice that received indicated treatments as displayed. Plasma concentration–time curves of CeO2@/Met in mice after intravenous injection. In vivo tissue distribution in B16F10 tumor-bearing mice intravenously injected with indicated treatments at different time points. Quantification of the metastatic nodules on the lung surface of mice under different treatments. Q-PCR analyzed the mRNA level of HIF-α in tumor tissues from B16F10 tumor-bearing mice subjected to indicated treatments. Relative intensity of HIF-1α protein expression by western blotting. Standardized uptake values (SUVs) in solid tumor regions obtained from in vivo PET images taken at 1 h after the injection of 18F-MISO. Relative quantification of MDSCs (CD11b+Gr-1+) in tumor tissues following different treatments. Relative quantification of CTLs (CD3+CD8+) in tumor tissues following different treatments. ELISA assay for IL-10 and TGF-β. Relative intensity of PD-L1 protein expression by western blotting. Histology of the mouse organs collected 21 days after the intravenous injection of CeO2@/Met (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c18180/suppl_file/am0c18180_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy

Lonidamine Liposomes to Enhance Photodynamic and Photothermal Therapy of Hepatocellular Carcinoma by Inhibiting Glycolysis

Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.

Liposomes Co-Loaded with Metformin and Chlorin E6 Modulate Tumor Hypoxia During Enhanced Photodynamic Therapy

Metformin Mediated PD‐L1 Downregulation in Combination with Photodynamic‐Immunotherapy for Treatment of Breast Cancer

Lipid-Polymer Hybrid Nanoparticles with Both PD-L1 Knockdown and Mild Photothermal Effect for Tumor Photothermal Immunotherapy

Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles

Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform

Size/Charge Changeable Acidity‐Responsive Micelleplex for Photodynamic‐Improved PD‐L1 Immunotherapy with Enhanced Tumor Penetration

Nanotechnology-mediated Immunochemotherapy Combined with Docetaxel and PD-L1 Antibody Increase Therapeutic Effects and Decrease Systemic Toxicity.

Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy

Preparation and effects of functionalized liposomes targeting breast cancer tumors using chemotherapy, phototherapy, and immunotherapy

Liposomal Oxaliplatin Prodrugs Loaded with Metformin Potentiate Immunotherapy for Colorectal Cancer.

Anti-PD1 Antibody and Not Anti-Lag-3 Antibody Improves the Antitumor Effect of Photodynamic Therapy for Treating Metastatic Breast Cancer

Catalase-based Liposomal for Reversing Immunosuppressive Tumor Microenvironment and Enhanced Cancer Chemo-Photodynamic Therapy.

Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.

Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition.

Boosting Anti-Pd-1 Therapy with Metformin-Loaded Macrophage-Derived Microparticles

Enhancing Photodynamic Therapy Efficacy Against Cancer Metastasis by Ultrasound-Mediated Oxygen Microbubble Destruction to Boost Tumor-Targeted Delivery of Oxygen and Renal-Clearable Photosensitizer Micelles.

Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief

Functional co-delivery nanoliposomes based on improving hypoxia for increasing photoimmunotherapy efficacy of cold tumors